[Tumor necrosis factor blocking agents: a review. Part II: safety and recommendations].
Blockade of tumor necrosis factor with monoclonal antibodies, has emerged as one of the most promising therapies in some autoimmune conditions as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and Crohn's disease. They have shown effectiveness on reducing symptoms and modifying the progression of the disease. However, they disrupt the balance of inflammatory and immune responses and some risks associated with TNF-blockers have become apparent. The purpose of this article is to review the evidence about benefits and risk associated with the use of TNF-blockers in approved indications and to provide practical recommendations for its use in the management of this conditions.
Rodríguez Moreno
C
C
Servicio de Farmacología Clínica, Complexo Hospitalario Universitario, Santiago de Compostela, A Coruña. carlos.rodriguez.moreno@sergas.es
López Vázquez
P
P
Durán Parrondo
C
C
Tato Herrero
F
F
Lado Lado
F
F
Velasco González
M
M
D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D012306:Risk; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha